

doi: 10.13241/j.cnki.pmb.2019.13.011

经鼓膜穿刺与肌肉注射鼠神经生长因子对突发性耳聋的治疗效果对比 *

李 红¹ 祝 康^{2△} 袁 婕³ 温晓妮⁴ 刘远新⁴

(1 西安体育学院健康科学系 陕西 西安 710068; 2 西安交通大学第二附属医院耳鼻喉科 陕西 西安 710004;

3 陕西省人民医院神经内科 陕西 西安 710068; 4 西安体育学院运动医学教研室 陕西 西安 710068)

摘要 目的:对比分析经鼓膜穿刺与肌肉注射鼠神经生长因子对突发性耳聋的治疗效果。**方法:**选择 2014 年 1 月~2016 年 12 月在西安体育学院健康科学系进行诊治的 75 例突发性耳聋患者, 将所有患者随机分为鼓膜穿刺组($n=37$ 例) 和肌肉注射组($n=38$ 例)。肌肉注射组患者采用肌肉注射的方法给予鼠神经生长因子治疗, 每次 $20 \mu\text{g}$, 每天 1 次; 鼓膜穿刺组患者采用经鼓膜穿刺方法给予治疗鼠神经生长因子治疗, 每次 $20 \mu\text{g}$, 每天 1 次。两组均治疗 14 d。比较两组的临床治疗效果、治疗前后纯音听阈值的变化及不良反应的发生情况。**结果:**治疗后, 鼓膜穿刺组痊愈 9 例, 显效 14 例, 有效 22 例, 无效 3 例, 有效率为 91.89% (34/37), 明显高于肌肉注射组[73.68% (28/38)]($P<0.05$) ; 两组纯音听阈值均与治疗前相比均明显降低($P<0.05$), 且鼓膜穿刺组明显低于肌肉注射组($P<0.05$)。两组突发性耳聋患者治疗过程中均未出现明显的不良反应。**结论:**经鼓膜穿刺鼠神经生长因子治疗突发性耳聋的临床效果明显优于肌肉注射, 且安全性较高。

关键词:鼓膜穿刺;肌肉注射;鼠神经生长因子;突发性耳聋

中图分类号:R764.43 文献标识码:A 文章编号:1673-6273(2019)13-2453-04

Comparison of the Effect of Tympanic Membrane Puncture and Intramuscular Injection of Rat Nerve Growth Factor in the Treatment of Sudden Deafness*

LI Hong¹, ZHU Kang^{2△}, YUAN Jie³, WEN Xiao-ni⁴, LIU Yuan-xin⁴

(1 Department of Health Sciences, Xi'an Physical Education University, Xi'an, Shaanxi, 710068, China;

2 Department of ENT, The Second Affiliated Hospital of Xi'an Jiao Tong University, Xi'an, Shaanxi, 710004, China;

3 Neurology Department, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi, 710068, China;

4 Department of Sports Medicine, Xi'an Physical Education University, Xi'an, Shaanxi, 710068, China)

ABSTRACT Objective: To compare the clinical effect of tympanic membrane puncture and intramuscular injection of rat nerve growth factor in the treatment of sudden deafness. **Methods:** 75 cases of patients with sudden deafness who were treated in Xi'an Physical Education University from January 2011 to December 2016 were selected and randomly divided into the tympanic membrane puncture group ($n=37$ case) and the intramuscular injection group ($n=38$ case). The intramuscular injection group was treated with intramuscular injection rat nerve growth factor, while the tympanic membrane puncture group was treated with tympanum puncture, $20 \mu\text{g}$ each time, 1 times a day. The clinical therapeutic effects, changes of pure tone threshold before and after treatment, and the incidence of adverse reactions were compared between the two groups. **Results:** After treatment, the effective rate of observation group was 91.89% (34/37), which was significantly higher than that of the control group [73.68% (28/38)]($P<0.05$); the pure tone hearing thresholds of both groups were significantly improved compared with those before treatment ($P<0.05$), which was significantly better in the tympanic membrane puncture group than that of the intramuscular injection group ($P<0.05$). There was no obvious adverse reactions in the two groups during the treatment. **Conclusion:** The clinical effect of mural puncture and mouse nerve growth factor on the sudden deafness is superior to that of the intramuscular injection, and the safety is high.

Key words: Tympanic membrane puncture; Intramuscular injection; Rat nerve growth factor; Sudden deafness

Chinese Library Classification(CLC): R764.43 Document code: A

Article ID: 1673-6273(2019)13-2453-04

前言

突发性耳聋作为临幊上常见的突发性神经性耳聋, 通常在数分钟、数小时内, 患者的听力降低至最低点, 听力下降幅度超

* 基金项目: 陕西省自然科学基金项目(2011JQ4022)

作者简介: 李红(1975-), 女, 硕士研究生, 副教授, 研究方向: 损伤康复, 电话: 13991243907, E-mail: lihong19751100@163.com

△ 通讯作者: 祝康(1981-), 男, 副主任医师, 研究方向: 耳聋的基础研究, 电话: 15829292533, E-mail: lihong19751100@163.com

(收稿日期: 2018-11-26 接受日期: 2018-12-23)

过 20 dB, 最少会累及邻近 2 个听力的检测频率^[1,2]。突发性耳聋发病原因不明, 有外界刺激和内部微循环的影响, 目前认为与循环障碍、病毒感染、血管阻塞性疾病、血浆纤维蛋白含量升高、自身免疫性疾病以及膜迷路破裂等密切相关^[3,4]。临幊上常用的治疗方法是注射鼠神经生长因子, 鼠神经生长因子与人类神经因子同源性极高, 具有维持神经细胞存活, 促进神经细胞分化和成熟等功能^[5-7]。

鼠神经生长因子不仅可以对正常神经细胞发挥营养因子功效, 还可以修复以及保护受到损伤的神经细胞, 因此被广泛应用于临幊治疗神经系统疾病的研究中^[8,9]。目前许多研究表明鼠神经生长因子在内耳的发育和成熟过程中都有不同程度的表达, 促进耳蜗神经轴突的再生, 保护并且修复。但其注射方式存在大很大的区别, 常规的注射是肌肉注射, 但是由于发挥作用的周期长, 最后作用于内耳的剂量几乎很少, 治疗效果不佳, 无法达到预期的效果。目前, 临幊上也采用鼓室内注射。本研究主要比较了经鼓膜穿刺与肌肉注射鼠神经生长因子对突发性耳聋的治疗效果, 结果报道如下。

1 资料与方法

1.1 一般资料

选择 2014 年 1 月~2016 年 12 月在西安体育学院健康科学系进行诊治的 75 例突发性耳聋患者, 均符合相关的诊断标准^[4], 排除伴有高血压、糖尿病、血液病和冠心病等基础代谢疾病者, 患有内听道、颅脑和中耳疾病者, 随机分为两组。鼓膜穿刺组 37 例, 男 20 例, 女 17 例; 年龄 22~69 岁, 平均 (40.35 ± 11.24) 岁; 病程 1~39 天, 平均 (14.39 ± 6.45) 天; 单侧发病 26 例, 双侧发病 11 例; 合并症: 眩晕 13 例, 耳鸣 20 例。肌肉注射组 38 例, 男 22 例, 女 16 例; 年龄 23~70 岁, 平均 (41.37 ± 10.93)

岁; 病程 1~38 天, 平均 (15.19 ± 7.38) 天; 单侧发病 26 例, 双侧发病 12 例; 合并症: 眩晕 14 例, 耳鸣 20 例。两组的基线资料对比无显著性差异 ($P > 0.05$), 具有可比性。

1.2 治疗方法

肌肉注射组采用肌肉注射的方法给予鼠神经生长因子(批号: 国药准字 S20100005, 生产厂家: 丽珠集团丽珠制药厂, 规格: 30 μg)治疗, 每次 20 μg, 每天 1 次; 鼓膜穿刺组采用经鼓膜穿刺方法给予治疗鼠神经生长因子治疗, 给药方法如下: 患者取仰卧位, 头部偏向健侧, 使患耳朝上, 首先对外耳道的耵聍进行仔细的清理, 并且使用 75% 的酒精对外耳道的皮肤进行消毒, 然后对鼓膜采取表面麻醉, 行鼓膜穿刺后, 把 20 μg 鼠神经生长因子缓慢注入患耳的鼓室中, 每天 1 次。疗程 14 d。

1.3 观察指标

临床治疗效果: ① 痊愈: 患者在 0.25~4 kHz 各频率听阈恢复正常听力水平; ② 显效: 在 0.25~4 kHz 中听力平均提高 > 30 dB; ③ 有效: 在 0.25~4 kHz 中听力平均提高幅度为 15~30 dB; ④ 无效: 在 0.25~4 kHz 中听力平均改善 < 15 dB。有效率 = (痊愈 + 显效 + 有效) / 总耳数 × 100%。检测治疗前后的纯音听阈值, 并观察不良反应发生率。

1.4 统计学分析

采用 SPSS15.00 软件进行数据分析, 计量资料以 $(\bar{x} \pm s)$ 示, 组间比较采用 t 检验, 计数资料以 % 表示, 组间比较行 χ^2 检验, 以 $P < 0.05$ 差异有统计学意义。

2 结果

2.1 两组临床疗效对比

治疗后, 鼓膜穿刺组的有效率为 91.89% (34/37), 明显高于肌肉注射组 [73.68% (28/38)] ($P < 0.05$), 见表 1。

表 1 两组临床疗效对比[例(%)]

Table 1 Comparison of the clinical effect between two groups[n(%)]

Groups	n	Recovery	Obviously effective	Effective	Invalid	Effective rate
Intramuscular injection group	38	5(13.16)	13(34.21)	10(26.32)	10(26.32)	73.68
Tympanic membrane puncture group	37	9(24.32)	14(37.84)	11(29.73)	3(8.11)	91.89*

Note: Compared with the intramuscular injection group, * $P < 0.05$.

2.2 两组治疗前后纯音听阈值对比

两组治疗后的纯音听阈值均较治疗前明显降低, 且鼓膜穿

刺组纯音听阈值明显低于肌肉注射组 ($P < 0.05$), 见表 2。

表 2 两组治疗前后纯音听阈值对比($\bar{x} \pm s$, dB)

Table 2 Comparison of the pure tone threshold before and after treatment between two groups($\bar{x} \pm s$, dB)

Groups	n	Before treatment	After treatment
Intramuscular injection group	38	69.43 ± 16.45	60.29 ± 15.32 [#]
Tympanic membrane puncture group	37	70.12 ± 18.37	49.58 ± 13.74**

Note: Compared with the intramuscular injection group, * $P < 0.05$, compared with before treatment, [#] $P < 0.05$.

2.3 两组不良反应发生情况对比

两组在治疗过程中均未出现明显的不良反应, 肌肉注射组 1 例发生眩晕, 伴有恶心、呕吐, 经过对症治疗后均缓解; 鼓膜穿刺组 2 例患者于用药后发生恶心呕吐、眩晕和耳鸣, 1 例发生短暂性耳痛, 经过对症治疗后均缓解。

3 讨论

突发性耳聋指的是原因不明的感音神经性听力损失, 按照患者的纯音听阈图, 听力曲线可以分为平坦型、低频型、全聋型以及高频型四个类型。患者的听力大多会于 3 d 内迅速显著降

低,常为中度或重度,以单侧发病最为多见,会伴有耳鸣、耳闷、恶心呕吐以及眩晕等不良反应。如果未得到及时的治疗(一般2周内治疗即可有效),极易发展为永久性耳聋。突发性耳聋治疗方法很多,根据不同的发病情况采取治疗,而且治疗的效果也存在差别。多数研究学者认为突发性耳聋是一种综合而非孤立的疾病^[10,11]。目前,临幊上常采用改善微循环、糖皮质激素、营养神经、抗病毒药物、高压氧和抗凝剂治疗,但尚未发现特别有效的治疗手段,临幊治疗方法也尚未统一^[12-14]。听力主要依靠耳蜗螺旋神经元的传导和毛细胞的感受。神经生长因子具有促突起生长以及神经元营养双重生物学功能,对中枢及周围神经元的分化、发育、生长、再生以及功能特性的表达均发挥着重要的生物调控功能。由于其可以提高受损神经细胞的存活率,临幊上主要用于治疗神经病变^[15-17]。研究表明鼠神经生长因子的治疗效果很可能是通过神经免疫网络间接对耳蜗神经以及耳蜗细胞发挥作用^[18,19]。

肌肉注射鼠神经生长因子在临幊上广泛应用于外伤后神经修复以及糖尿病外周神经病变等外周神经病变的治疗,并取得了较好的治疗效果^[20-22]。但是采取肌肉注射鼠神经生长因子的治疗效果不佳,由于多次的臀位肌注,导致注射部位出现强烈的疼痛,而且患者也无法忍受,会中断治疗,拒绝注射^[23-25]。而经鼓膜穿刺注射鼠神经生长因子可以通过蜗窗膜的主动吸收或短距离渗透作用进入内耳中,使螺旋神经节细胞、内耳毛细胞以及支持细胞的内源性神经生长因子得到补充,恢复内耳功能,从而发挥治疗突发性耳聋的目的^[26,27]。

本研究结果显示鼓膜穿刺组的有效率明显高于肌肉注射组,治疗后的纯音听阈值显著高于肌肉注射组,表明与肌肉注射的给药方式相比,经鼓膜穿刺鼠神经生长因子可以显著提高突发性耳聋的临床治疗效果。分析其原因可能鼓膜穿刺注射法目的性强,直接作用于损伤的部位,能保持药物的浓度,达到治疗的效果。而且鼓膜穿刺治疗期间出现的不良反应少,安全性高。鼠神经生长因子进而可以与内耳相应的受体发生特异性结合,发挥营养神经、促进内耳功能的迅速恢复的临床治疗效果^[28-30]。

综上所述,经鼓膜穿刺鼠神经生长因子治疗突发性耳聋的临床效果明显优于肌肉注射方式,且安全性较高。

参考文献(References)

- [1] Kitoh R, Nishio S Y, Ogawa K, et al. Nationwide epidemiological survey of idiopathic sudden sensorineural hearing loss in Japan [J]. *Acta Otolaryngol*, 2017, 137(sup565): 1-9
- [2] Malcolm K, Chen J C, Juen-Haur H. Risk of peripheral artery occlusive disease in patients with vertigo, tinnitus, or sudden deafness: a secondary case-control analysis of a nationwide, population-based health claims database[J]. *Plos One*, 2016, 11(9): e0162629
- [3] Min S K, Shin J H, Chang M Y, et al. Impact of control of blood glucose level during treatment of sudden deafness in diabetics: relationship with prognosis[J]. *Eur Arch Otorhinolaryngol*, 2017, 274 (3): 1339-1343
- [4] Yan D, Tekin D, Bademci G, et al. Spectrum of DNA variants for non-syndromic deafness in a large cohort from multiple continents[J]. *Human Genetics*, 2016, 135(8): 1-9
- [5] Hosokawa S, Sugiyama K, Takahashi G, et al. Prognostic factors for idiopathic sudden sensorineural hearing loss treated with hyperbaric oxygen therapy and intravenous steroids[J]. *Journal of Laryngology & Otology*, 2017, 131(1): 77-82
- [6] Zhao P, Li E. Study of acupuncture combined with rat nerve growth factor on neurobehavioral ability of cerebral palsy infant rats and its brain tissue growth and metabolism associated proteins [J]. *Chinese acupuncture & moxibustion*, 2018, 38(6): 631
- [7] Yang H U, Yan Z, Kang T, et al. Effects of nerve growth factor and basic fibroblast growth factor dual gene modification on rat bone marrow mesenchymal stem cell differentiation into neuron-like cells in vitro[J]. *Molecular Medicine Reports*, 2016, 13(1): 49-58
- [8] Ralli M, Greco A, Falasca V, et al. Recovery from repeated sudden hearing loss in a patient with takayasu's arteritis treated with hyperbaric oxygen therapy: the first report in the literature [J]. *Case Rep Otolaryngol*, 2017, 2017(1): 3281984
- [9] Fasano T, Pertinhez T A, Tribi L, et al. Laboratory assessment of sudden sensorineural hearing loss: A case-control study [J]. *Laryngoscope*, 2017, 127(10): 2375
- [10] Chen K, Liang S, Ling Z, et al. GJB2, and mitochondrial 12S rRNA susceptibility mutations in sudden deafness [J]. *European Archives of Oto-Rhino-Laryngology*, 2016, 273(6): 1-6
- [11] Okada M, Hato N, Nishio S Y, et al. The effect of initial treatment on hearing prognosis in idiopathic sudden sensorineural hearing loss: a nationwide survey in Japan[J]. *Acta Otolaryngol*, 2017, 137(sup565): 1-4
- [12] Cho T Y, Cheng P W, Young Y H. Evolution of postirradiated sudden deafness in nasopharyngeal carcinoma survivors during the past two decades[J]. *Laryngoscope*, 2016, 126(9): 2016-2021
- [13] Ajduk J, Ries M, Tropic R, et al. Hyperbaric oxygen therapy as salvage therapy for sudden sensorineural hearing loss [J]. *Journal of International Advanced Otology*, 2017, 13(1): 61-64
- [14] Lee J S, Hong S K, Kim D H, et al. The neutrophil-to-lymphocyte ratio in children with sudden sensorineural hearing loss: a retrospective study[J]. *Acta Otolaryngol*, 2017, 137(1): 1-4
- [15] Zarandy M M, Ashtiani M T, Bastaninejad S, et al. Prognosticating hearing outcome in patients with idiopathic sudden sensorineural hearing loss by means of otoacoustic emissions and auditory brainstem response[J]. *Ear Nose Throat J*, 2017, 96(12): E1-E5
- [16] Suzuki M, Inage K, Sakuma Y, et al. Effect of administration of antibodies against nerve growth factor in a rat model of muscle injury [J]. *Injury-international Journal of the Care of the Injured*, 2016, 47 (3): 609-612
- [17] Mesentierlouro L A, Nicolò S D, Rosso P, et al. Time-dependent nerve growth factor signaling changes in the rat retina during optic nerve crush-induced degeneration of retinal ganglion cells [J]. *International Journal of Molecular Sciences*, 2017, 18(1): 98
- [18] Labranche T P, Bendele A M, Omura B C, et al. Nerve growth factor inhibition with tanezumab influences weight-bearing and subsequent cartilage damage in the rat medial meniscal tear model [J]. *Annals of the Rheumatic Diseases*, 2017, 76(1): 295
- [19] Rosso P, Moreno S, Fracassi A, et al. Nerve growth factor and autophagy: effect of nasal anti-NGF-antibodies administration on

- Ambra1 and Beclin-1 expression in rat brain [J]. *Growth Factors*, 2016, 33(5-6): 1
- [20] Song J N, Liu Z W, Sui L, et al. Dynamic expression of nerve growth factor and its receptor Trk A after subarachnoid hemorrhage in rat brain[J]. *Neural Regeneration Research*, 2016, 11(8): 1278
- [21] Wood R L, Karlinsey K S, Thompson A D, et al. Baseline effects of lysophosphatidylcholine and nerve growth factor in a rat model of sciatic nerve regeneration after crush injury [J]. *Neural Regeneration Research*, 2018, 13(5): 846
- [22] Stepanichev M, Onufriev M, Aniol V, et al. Effects of cerebrolysin on nerve growth factor system in the aging rat brain [J]. *Restorative Neurology & Neuroscience*, 2017, 35(6): 571-581
- [23] Tarnawski A S, Ahluwalia A, Jones M K, et al. Expression of nerve growth factor in rat stomach. Implications for interactions between endothelial, neural and epithelial cells [J]. *Journal of Physiology & Pharmacology An Official Journal of the Polish Physiological Society*, 2016, 67(6): 879
- [24] Matsumine H, Sasaki R, Tabata Y, et al. Facial nerve regeneration using basic fibroblast growth factor-impregnated gelatin microspheres in a rat model [J]. *Journal of Tissue Engineering & Regenerative Medicine*, 2016, 10(10): E559-E567
- [25] Wei L, Ren Q, Zhang Y, et al. Effects of hyperbaric oxygen and nerve growth factor on the long-term neural behavior of neonatal rats with hypoxic ischemic brain damage [J]. *Acta Cirurgica Brasileira*, 2017, 32(4): 270-279
- [26] Lee H A, Ji E K, Ji E S, et al. Asparagus cochinchinensis stimulates release of nerve growth factor and abrogates oxidative stress in the Tg2576 model for Alzheimer's disease [J]. *Bmc Complement Altern Med*, 2018, 18(1): 125
- [27] Jing Y, Zhang W, Wang Y, et al. Effect comparison of mouse nerve growth factor injection via different methods for treating sudden deafness[J]. *China Medical Herald*, 2016, 13(15): 127-130
- [28] Yaşar M, Kaya A, Karaman H, et al. Potential Curative Role of Hypericum Perforatum in an Experimental Rat Model of Tympanic Membrane Perforation[J]. *Journal of International Advanced Otology*, 2016, 12(3): 252
- [29] Hong M, Wang S. Through ear endoscope tympanic membrane puncture method to explore clinical nursing for the treatment of secretory otitis media[J]. *Chinese Community Doctors*, 2017, 33(32): 117-117
- [30] Deng S, Liu J, Liu T, et al. Comparison between auripuncture or tympanostomy tubes combined with adenoidectomy in children with otitis media with effusion [J]. *Chinese Archives of Otolaryngology-Head and Neck Surgery*, 2016, 2016, 23(6): 318-320

(上接第 2447 页)

- [8] Deepa P R, Varalakshmi P. Atheroprotective effect of exogenous heparin-derivative treatment on the aortic disturbances and lipoprotein oxidation in hypercholesterolemic diet fed rats[J]. *Clinica Chimica Acta*, 2005, 355(1): 119-130
- [9] 王慧云, 赵军香, 张丽荣. 自拟健脾泄浊方联合依折麦布辛伐他汀片治疗高脂血症的疗效及其对血管内皮功能的影响[J]. 现代中西医结合杂志, 2016, 25(13): 1463-1465
- [10] 赵秀敏, 李风学, 谷婧. 脂康颗粒治疗高脂血症的临床研究 [J]. 中国医药导报, 2017, 14(20): 117-119, 124
- [11] 向兴刚, 安杨. 化痰脉通片治疗急性期高血压脑出血的临床研究 [J]. 新疆中医药, 2017, 35(02): 12-15
- [12] 孙敬雯, 陈苗苗, 洪军. 化痰脉通片对高脂血症大鼠血脂、脑脂代谢的影响[J]. 广东药科大学学报, 2018, 34(01): 55-58
- [13] 万智, 全森. 沈宝藩教授辨治高脂血症思路探析 [J]. 新疆中医药, 2018, 36(01): 40-42
- [14] 向兴刚, 安杨. 中西医结合治疗急性期高血压脑出血的临床疗效观察[J]. 中西医结合心脑血管病杂志, 2017, 15(14): 1707-1709
- [15] 张莉晶. 化痰脉通片治疗 H 型高血压痰瘀互结证的临床研究[D]. 新疆医科大学, 2017
- [16] 施超, 王星, 朱鸿玲. 血脂康胶囊联合氟伐他汀钠治疗高脂血症的临床观察[J]. 世界临床药物, 2018, 39(01): 43-46+4
- [17] 刘宁, 黄宇玲, 刘杰, 等. 氟伐他汀缓释片治疗血脂异常合并冠心病的疗效观察 [J]. 中西医结合心脑血管病杂志, 2017, 15(19): 2425-2427
- [18] 张瑞凤. 僵蚕醇提物对棉铃虫的毒杀作用及其机理研究[D]. 西北农林科技大学, 2013
- [19] 潘雪, 马端鑫, 李燕, 等. 水蛭药理作用的研究进展[J]. 中国民族民间医药, 2015, 24(14): 24-25
- [20] 田硕, 苗明三. 牛膝的化学、药理及应用特点探讨[J]. 中医学报, 2014, 29(8): 1186-1188
- [21] 任清波, 邬述玲, 陈晶晶, 等. 非酒精性单纯性脂肪肝患者肝功及血脂代谢情况分析[J]. 山东医药, 2016, 56(17): 92-93
- [22] 薛雷, 李保义, 吴俊英. 保肝消脂汤对非酒精性脂肪肝大鼠脂代谢及肝功能的影响[J]. 辽宁中医杂志, 2015, 42(11): 2236-2239
- [23] 张晓红. 肝功与血脂血清学指标水平检验在脂肪肝诊断中的应用分析[J]. 中外医学研究, 2015, 13(10): 56-58
- [24] Lee H S, Nam Y, Chung Y H, et al. Beneficial effects of phosphatidylcholine on high-fat diet-induced obesity, hyperlipidemia and fatty liver in mice[J]. *Life Sciences*, 2014, 118(1): 7-14
- [25] Tziomalos K, Athyros V G, Paschos P, et al. Nonalcoholic fatty liver disease and statins[J]. *Metabolism-clinical & Experimental*, 2015, 64(10): 1215-1223
- [26] 党志博, 党中勤, 王宇亮, 等. 中西医结合治疗乙型肝炎慢加急性肝功能衰竭临床研究[J]. 中医学报, 2017, 32(8): 1491-1494
- [27] 杨翠荣. 郁金药理及中医临床应用略述 [J]. 光明中医, 2014, 29(08): 1772-1773
- [28] 郭晓庆, 孙佳明, 张辉. 水蛭的化学成分与药理作用 [J]. 吉林中医药, 2015, 35(1): 47-50
- [29] 刘瑞坤. 半夏白术汤对高血压患者血压、血脂的影响[J]. 中西医结合心血管病电子杂志, 2016, 4(2): 10-10
- [30] 何秋月. 二地天麻半夏汤治疗糖尿病合并高血压阴虚阳亢夹痰证的临床研究[D]. 南京中医药大学, 2017